- Home
- KNOP vs NBTX Comparison
KNOP vs NBTX Comparison
Compare KNOP & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- NBTX
- Stock Information
- Founded
- KNOP 2013
- NBTX 2003
- Country
- KNOP United Kingdom
- NBTX France
- Employees
- KNOP N/A
- NBTX N/A
- Industry
- KNOP Marine Transportation
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- NBTX Health Care
- Exchange
- KNOP Nasdaq
- NBTX Nasdaq
- Market Cap
- KNOP 199.5M
- NBTX 201.9M
- IPO Year
- KNOP 2013
- NBTX 2020
- Fundamental
- Price
- KNOP $5.40
- NBTX $3.07
- Analyst Decision
- KNOP
- NBTX Strong Buy
- Analyst Count
- KNOP 0
- NBTX 1
- Target Price
- KNOP N/A
- NBTX $12.00
- AVG Volume (30 Days)
- KNOP 50.7K
- NBTX 13.0K
- Earning Date
- KNOP 03-20-2025
- NBTX 04-23-2025
- Dividend Yield
- KNOP 1.93%
- NBTX N/A
- EPS Growth
- KNOP N/A
- NBTX N/A
- EPS
- KNOP N/A
- NBTX N/A
- Revenue
- KNOP $299,790,000.00
- NBTX $45,220,186.00
- Revenue This Year
- KNOP $7.66
- NBTX N/A
- Revenue Next Year
- KNOP $2.29
- NBTX N/A
- P/E Ratio
- KNOP N/A
- NBTX N/A
- Revenue Growth
- KNOP 4.75
- NBTX 526.17
- 52 Week Low
- KNOP $4.94
- NBTX $2.76
- 52 Week High
- KNOP $9.11
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- KNOP 42.72
- NBTX 38.51
- Support Level
- KNOP $5.39
- NBTX $2.95
- Resistance Level
- KNOP $5.79
- NBTX $3.47
- Average True Range (ATR)
- KNOP 0.22
- NBTX 0.23
- MACD
- KNOP 0.00
- NBTX -0.07
- Stochastic Oscillator
- KNOP 21.57
- NBTX 12.92
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.